Filing summary
Entity discrepancy: The request identifies Accendra Health Inc., but the supplied Form 10-Q is for Owens & Minor, Inc. This summary reflects the filing text provided, not an Accendra Health filing.
Business context and reporting period
Quarterly report for the three and nine months ended September 30, 2016, compared with the same periods in 2015. Owens & Minor describes itself as a global healthcare services company. Its reporting segments are Domestic (U.S. distribution, logistics and value-added services), International (European distribution and related services), and Clinical & Procedural Solutions (CPS; including surgical and procedural kitting and sourcing).
Financial results and liquidity
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Net revenue | $2,415.6 million | $2,471.7 million | $7,355.1 million | $7,285.0 million |
| Gross margin | $296.3 million (12.27%) | $306.4 million (12.39%) | $892.3 million (12.13%) | $902.3 million (12.39%) |
| Operating earnings, GAAP | $53.6 million | $53.6 million | $150.6 million | $142.4 million |
| Net income | $29.8 million | $28.2 million | $81.7 million | $71.3 million |
| Diluted EPS | $0.48 | $0.45 | $1.32 | $1.14 |
| Adjusted diluted EPS (non-GAAP) | $0.51 | $0.54 | $1.53 | $1.44 |
For the first nine months, operating cash flow was $143.8 million, down from $206.0 million; investing cash outflow was $16.3 million versus $32.1 million; financing cash outflow was $82.1 million versus $103.1 million. Cash increased by $52.1 million to $213.1 million at September 30, 2016. The company attributed the operating cash flow decline mainly to working-capital movements, including effects of a customer exit, and prior-year vendor payment timing.
At September 30, current assets were $2,020.8 million and current liabilities were $1,093.8 million. Long-term debt, excluding current portion, was $566.5 million. The company had $550 million of senior notes due 2021 and 2024, no revolving-credit borrowings, and $445 million of revolver availability after letters of credit. Management stated it was in compliance with debt covenants. Nine-month capital expenditures were $20.8 million; cash dividends paid were $47.8 million and share repurchases were $48.7 million.
Material changes versus prior comparable periods
- Q3 revenue fell 2.3%, while nine-month revenue rose 1.0%. Q3 net income increased 5.9%; nine-month net income increased 14.5%.
- Gross margin declined in both comparisons, to 12.27% from 12.39% in Q3 and to 12.13% from 12.39% year to date. Management cited lower manufacturer price-change income, the exit of a large domestic customer, foreign exchange, and customer cost pressures.
- Q3 GAAP operating earnings were essentially unchanged; nine-month operating earnings rose about 5.8%. Adjusted EPS declined $0.03 in Q3 but increased $0.09 year to date.
- Domestic revenue decreased 1.5% in Q3 but increased 1.5% year to date. International revenue decreased 9.7% and 9.0%, respectively. CPS revenue declined 7.8% in Q3 and was essentially flat year to date.
- Domestic operating earnings decreased in Q3 but increased year to date; International operating earnings improved year to date, while CPS operating earnings declined in both comparisons.
- The effective tax rate decreased to 36.3% for Q3 and 37.3% year to date, from 39.8% and 41.6%, respectively. The company attributed the change to a greater share of pretax income in lower-tax jurisdictions and tax deductibility of certain prior-year acquisition charges.
- Cash repurchases increased year over year. The company repurchased about 1.4 million shares for $48.7 million during the first nine months and had $21.3 million remaining under the then-current authorization at September 30.
Outlook, commentary, risks and unusual items
- Management expects the large domestic customer exit to weigh on revenue and gross margin in Q4 2016 and into 2017, and expects increased gross-margin pressure from healthcare cost containment and competition. CPS cited temporary production capacity and workforce challenges in Q3.
- No specific numerical earnings or revenue guidance is provided in the supplied filing text. Management said available operating cash flow, cash and revolver capacity should be sufficient for working capital, capital expenditures, strategic growth, debt and lease obligations, dividends, and repurchases.
- Acquisition-related and exit/realignment charges were $2.7 million in Q3 and $20.0 million year to date. Year-to-date realignment charges included severance, including a voluntary employee separation program, and costs to streamline administrative functions; the filing also reports additional costs expensed as incurred.
- In October 2016, the board authorized a new share repurchase program of up to $100 million, effective after completion or expiration of the existing authorization.
- The filing identifies Brexit-related uncertainty as a risk to European operations, trade, currencies, customers and suppliers. Other cited risks include customer concentration and retention, pricing pressure, supplier funding and terms, foreign exchange, fuel prices, regulation, acquisitions, information systems and cybersecurity, litigation, and financing access or costs.
- The company reported no material developments in the legal proceedings described in its 2015 Form 10-K. It also reported $9.6 million of unrecognized tax-benefit liabilities at September 30, 2016.
- Disclosure controls and procedures were assessed as effective as of September 30, 2016; no material change in internal control over financial reporting was reported during the quarter.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Owens & Minor, Inc., not Accendra Health Inc.
- Track the financial and customer impact of the large customer exit and the expected Q4 and 2017 gross-margin pressure.
- Assess whether lower operating cash flow reflects temporary working-capital timing or a more persistent trend.
- Review segment performance, particularly International revenue declines and CPS production constraints.
- Monitor the use of remaining and newly authorized share repurchase capacity alongside dividends, debt, and liquidity needs.
- Follow Brexit, currency and trade developments, and the outcome and timing of the company’s tax contingencies.